In addition, based on prior clinical experience using other inhibitors in lung cancer (e.g., switching crizotinib to alectinib [29] or gefitinib to osimertinib [30]), AML cells will almost certainly acquire further resistance to the next-generation FLT3 inhibitors through additional mutations. Here, FLT3 is linked to lung carcinoma.